


Figure 1. Indications for Prostate Biopsy Following DRE and Total PSA Screen



Patient informed consent for screening is encouraged. High risk of prostate cancer is based on age, race, and family history (see text for details). Options shown for cases with non-suspicious DRE and total PSA in the 4.1-10.0 ng/mL range can be selected at the discretion of the urologist. This algorithm is intended as a guide for using Quest Diagnostics laboratory tests to determine when to perform prostate biopsy. It is based on the National Comprehensive Cancer Network guidelines.¹¹ The algorithm is provided for informational purposes only and is not intended as medical advice. A physician's test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.